Feature | Women's Health | July 03, 2019 | By Samir Parikh

Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine

Countless possibilities can impact the future of global healthcare and AI is the first step toward breakthrough that will change the landscape of personalized medicine

Contrary to what many people believe, artificial intelligence (AI) has played a role in breast screening technology for a number of years. Hologic, for example, has been leveraging AI in device development as early as 2006, when it trained its first piece of technology to classify a patient’s breast density through breast tissue pattern and texture analysis. More than a decade later, AI has continued to progress. The benefit of time has not only allowed R&D professionals to learn more about the technology, but has also allowed the AI technology to become more precise thanks to the growing body of images in the database. The industry has carefully watched AI’s technological evolution, slowly showing its support as more benefits are realized, and today we’re seeing many radiologists lean in and embrace AI with open arms.

 

AI’s Impact on Breast Cancer Screening

During the 2018 Radiological Society of North America (RSNA) annual meeting, Hologic polled more than 300 attendees, including radiologists and radiology administrative professionals, and found that all participants agreed that there is an application for AI in breast cancer screening. Additionally, respondents indicated that AI will have the greatest impact in the future on personalized screening pathways through the creation of new risk models. While AI very much has a present-day application, it’s clear that its greatest impact is still yet to come as we strive to deliver more personalized care.

Currently, as we all know, there are standard breast screening guidelines for the “average risk” patient without any known risk factors like a family history of breast cancer and increasing patient age. These are two of the biggest risk factors among building a unique profile indicating how “at-risk” a patient really is, and all factors combined can subsequently influence an individual’s screening protocol — including the age she starts, frequency and even the imaging modality for screening.

Breast density is a specific example of a risk factor where AI is particularly useful for determining a patient’s screening pathway. Women with very dense breasts are four to five times more likely to develop breast cancer than women with less dense breasts, making it important to be able to classify each patient’s density.1,2 Doing so requires the patient to get a mammogram, though. Without AI, radiologists must visually assess the images from the exam to determine a woman’s breast density using the Breast Imaging Reporting and Data System (BI-RADS) founded by the American College of Radiology (ACR) in 1993. Utilizing AI technology, however, removes any subjectivity associated with this manual process by automatically categorizing each patient’s density based on the thousands of breast images that it is trained by radiologists to know. As a result, radiologists can more confidently provide the most appropriate screening plan for each individual moving forward.

Aside from breast density, it has also been suggested in more recent studies that parenchymal texture features, which are measures of the local distribution of the parenchymal tissue, may also provide complementary information regarding an individual woman’s risk for breast cancer.3,4 This is yet another example of how risk stratification is being used, for which AI can offer assistance.

 

AI and Risk Assessment

AI will continue to play a significant role in risk stratification and risk assessment to drive more personalized patient care and outcomes. Patient history, family history, evidence-based clinical conditions, image-based phenotypes (e.g. texture/pattern/AI based features) and many more such attributes and innovations will further augment and strengthen the personalized health profile assessment along with risk models. There are countless possibilities to impact the future of global healthcare and our journey in AI is the first big step toward breakthrough that will change the landscape of personalized medicine. It’s not a matter of “if,” it’s a matter of when.

 

Samir Parikh is the global vice president of research and development for Hologic. In this role, he is responsible for leading and driving innovative advanced solutions across the continuum of care to drive sustainable growth of the Breast and Skeletal Health Division.

 

References:

1. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 356(3):227-36, 2007.

2. Yaghjyan L, Colditz GA, Collins LC, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst. 103(15):1179-89, 2011.

3. H. Li et al., “Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms,” Acad. Radiol. 12(7), 863–873 (2005).

4. Manduca et al., “Texture features from mammographic images and risk of breast cancer,” Cancer Epidemiol. Biomarkers Prev. 18(3), 837–845 (2009).


Related Content

News | Artificial Intelligence

February 28, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered solutions that enable medical providers ...

Time February 28, 2024
arrow
News | Women's Health

February 27, 2024 — Hologic, Inc. continues to deliver on its commitment to advancing women’s health by unveiling new ...

Time February 27, 2024
arrow
News | Breast Imaging

February 23, 2024 — ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European ...

Time February 23, 2024
arrow
News | Breast Imaging

February 22, 2024 — The FAST-Forward randomized trial from the UK found that ultrahypofractionated whole breast ...

Time February 22, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | FDA

February 15, 2024 — Merit Medical Systems, Inc., a global leader of healthcare technology, has received US Food and Drug ...

Time February 15, 2024
arrow
News | Breast Imaging

February 9, 2024 — An innovative breast imaging technique provides high sensitivity for detecting cancer while ...

Time February 09, 2024
arrow
News | Radiology Business

February 1, 2024 — Theragenics Corporation, a global leader in minimally invasive brachytherapy, interventional devices ...

Time February 01, 2024
arrow
News | FDA

January 30, 2024 — IceCure Medical Ltd. has announced the U.S. Food and Drug Administration (FDA) has responded ...

Time January 30, 2024
arrow
News | Breast Imaging

January 29, 2024 — Diagnoses of breast cancer have increased steadily in women under age 50 over the past two decades ...

Time January 29, 2024
arrow
Subscribe Now